MSD embarks on long-term production in VN
The pharmaceutical corporation, Merck Sharp & Dohme Corp. (widely
known MSD), plans to establish a 100 percent foreign-invested company in
Vietnam this year in anticipation of the country’s rising demand
for medicines.
The pharmaceutical corporation, Merck Sharp & Dohme Corp. (widely
known MSD), plans to establish a 100 percent foreign-invested company in
Vietnam this year in anticipation of the country’s rising demand
for medicines.
MSD Vice Chairman for the Asian region Craig Kelly unveiled the plan at an inauguration ceremony of the group’s new headquarters in Ho Chi Minh City on Jan. 20.
Kelly said Vietnam is a market of high potential as it has a fast growing economy, a large and young population and its demand for high-quality pharmaceutical products is rising.
“ Vietnam is an important market for MSD in the Asia-Pacific region,” he noted.
With its two representative offices in Ho Chi Minh City and Hanoi , MSD currently acts as the supplier of vaccines and medicines for cardiovascular disease, diabetes, infectious diseases, hepatitis, asthma, and cervical cancer.
“We will focus on enhancing our capacity on clinical research and producing new products for patients as well as the health community in Vietnam ,” the executive said.
MSD is the first company to introduce vaccine for cervical cancer in Vietnam . It presented more than 29,000 doses of anti-cervical cancer vaccine to the Central Hygiene and Epidemiology and Institute./.
MSD Vice Chairman for the Asian region Craig Kelly unveiled the plan at an inauguration ceremony of the group’s new headquarters in Ho Chi Minh City on Jan. 20.
Kelly said Vietnam is a market of high potential as it has a fast growing economy, a large and young population and its demand for high-quality pharmaceutical products is rising.
“ Vietnam is an important market for MSD in the Asia-Pacific region,” he noted.
With its two representative offices in Ho Chi Minh City and Hanoi , MSD currently acts as the supplier of vaccines and medicines for cardiovascular disease, diabetes, infectious diseases, hepatitis, asthma, and cervical cancer.
“We will focus on enhancing our capacity on clinical research and producing new products for patients as well as the health community in Vietnam ,” the executive said.
MSD is the first company to introduce vaccine for cervical cancer in Vietnam . It presented more than 29,000 doses of anti-cervical cancer vaccine to the Central Hygiene and Epidemiology and Institute./.
You should also see
World economy’s recovery drives Vietnam’s exports
With the recovery of the world market and increasing orders, Vietnam's import and export activities in the first quarter of 2024 prospered and achieved positive results.
See more
Business
Cam Lam - Vinh Hao Expressway to help drive south-central region's economy
The 78.5km Cam Lam - Vinh Hao Expressway, one of the three sub-projects of the North - South Expressway project’s eastern wing, officially opened to traffic on April 26.
Business
Vietnam needs drastic reforms to create firm ground for economic growth: experts
Drastic institutional reforms are needed to create firm ground for economic growth in the context that persistent challenges, both external and internal, still cloud the growth prospect, experts have said.
Business
Dak Lak firm pioneers in following EUDR in coffee production
The Dak Lak September 2 Import-Export Company Limited (Simexco) has pioneered in building coffee growing areas following the EU Deforestation Regulation (EUDR), it announced on April 25.
Business
Energy industry needs nearly 5 trillion VND of investment in 2021-2030
The total investment capital demand for the whole energy sector in the 2021-2030 period is between 4.13-4.8 trillion VND (163.01-189.46 million USD), according to a plan to implement the National Power Planning in the 2021-2030 period with a vision to 2050.
Business
Dong Nai calls for Korean investment into green growth
The southern province Dong Nai introduced its investment projects and incentives to the Republic of Korea (RoK)’s firms at a workshop in Seoul on April 25.
